Biological treatment for erythrodermic psoriasis.
Dogra S, Mehta H.
Expert Opin Biol Ther. 2022 Dec;22(12):1531-1543. doi: 10.1080/14712598.2022.2128669. Epub 2022 Sep 28.
Psoriasis: a brief overview.
Raharja A, Mahil SK, Barker JN.
Clin Med (Lond). 2021 May;21(3):170-173. doi: 10.7861/clinmed.2021-0257.
Updates on the Treatment of Erythrodermic Psoriasis.
Lo Y, Tsai TF.
Psoriasis (Auckl). 2021 Jun 9;11:59-73. doi: 10.2147/PTT.S288345. eCollection 2021.
Psoriasis.
Weigle N, McBane S.
Am Fam Physician. 2013 May 1;87(9):626-33.
[Erythrodermic psoriasis].
Rollin L, Rioual N, Aubret J, Dolghin M, Fouilland X.
Rev Prat. 2024 Jan;74(1):56-57.
Erythrodermic psoriasis improved by Tildrakizumab.
Trevisan G, Germi L, Naldi L.
Dermatol Reports. 2022 Nov 23;14(4):9448. doi: 10.4081/dr.2022.9448. eCollection 2022 Nov 21.
Erythrodermic psoriasis after COVID-19 vaccination.
Trepanowski N, Coleman EL, Melson G, Brem CE, Lam CS.
JAAD Case Rep. 2022 Oct;28:123-126. doi: 10.1016/j.jdcr.2022.07.041. Epub 2022 Aug 10.
Erythrodermic psoriasis.
Mumoli N, Vitale J, Gambaccini L, Sabatini S, Brondi B, Cei M.
QJM. 2014 Apr;107(4):315. doi: 10.1093/qjmed/hct139. Epub 2013 Jun 12.
Erythrodermic Psoriasis Managed with Risankizumab.
Alajlan A, Madani A, Qadoumi TA, Aljaloud A, Alessa M.
Case Rep Dermatol. 2022 Aug 19;14(2):219-224. doi: 10.1159/000525774. eCollection 2022 May-Aug.
Targeted Treatment for Erythrodermic Psoriasis: Rationale and Recent Advances.
Shao S, Wang G, Maverakis E, Gudjonsson JE.
Drugs. 2020 Apr;80(6):525-534. doi: 10.1007/s40265-020-01283-2.
